Exelixis, Inc. (EXEL) has a MoatMap StockRank of 99/100 based on Quality (87/100), Value (45/100), and Momentum (72/100) factor scores. The current signal is STRONG BUY. Exelixis, Inc. is a high-quality healthcare company (Q:87), but it does not present a clear asymmetric opportunity driven by the identified macro themes for the next 18 months. While healthcare is generally resilient, there isn't a specific unpriced tailwind or contrarian angle here. The valuation score (V:45) suggests it may not be a 'growth-at-a-reasonable-price' story, and its sector is not directly impacted by the current geopolitical/liquidity shifts in a way that suggests outsized, unpriced gains.
Exelixis, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative small molecule therapies for cancer. Its competitive strength stems from its flagship oncology product, CABOMETYX, and a robust pipeline targeting various cancer indications, establishing it as a significant player in the oncology therapeutics market.
| Price | $50.15 |
| Market Cap | $12.6B |
| P/E (TTM) | 16.12 |
| P/E (Forward) | 12.02 |
| Price/Book | 6.38 |
| Return on Equity | 41.0% |
| Return on Invested Capital | 36.6% |
| Debt/Equity | 8.76 |
| Gross Margin | 96.4% |
| Operating Margin | 41.1% |
| Revenue Growth | 10.0% |
| Free Cash Flow | $629M |
Exelixis, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).